CA-SYNACK
28.5.2019 07:50:07 CEST | Business Wire | Press release
Synack, the most trusted Crowdsourced Penetration Testing company, announced today it is now both CREST Accredited for penetration testing services and a CREST Member company in the USA. This is further recognition of Synack as the market leader in delivering the most effective, efficient penetration test.
CREST is a not-for-profit accreditation and certification body that represents and supports the technical information security market. CREST was set up in 2006 in response to the clear need for more regulated professional services with known, dependable quality, and is now recognized globally as the cyber assurance body for the technical security industry. CREST has become the respected standard for penetration testing in countries across the world, where it is increasingly a mandatory requirement for companies that have the most stringent security requirements such as government and financial services. Synack has researchers in more than 60 of these countries.
“This accreditation demonstrates that Synack’s crowdsourced penetration testing follows well-established best practices while using software and the world’s best security researchers,” said Dr. Mark Kuhr, Synack CTO and co-founder. “CREST’s accreditation examination determines if an organization meets its risk assessment, technical capability, and code of conduct standards. The CREST organisation clearly understands the challenges enterprises face today in scaling their security practices, and is supporting the G2000 by accrediting Synack to support these challenges. We appreciate the acknowledgement that Synack meets all of those critical requirements.”
Synack has prioritized trust, quality and insights as critical characteristics of a penetration test. The accreditation process determines if an organization meets risk assessment, technical capability, and code of conduct standards. Relative to a traditional penetration test, Synack believes that the crowdsourced approach provides additional testing rigor, enhanced technology, and deeper visibility and control.
“The CREST accreditation provides further recognition of Synack penetration testing, offering the highest levels of technical quality and testing rigor“ said David Charlton, Synack’s Chief Product Strategist and former Head of Penetration Testing at JPMorgan Chase & Co.
Not only does CREST offer an independent, third party assessment of a company’s penetration testing capabilities, it also provides researchers with the opportunity to become CREST qualified researchers. Synack’s crowd includes CREST certified penetration testers. Synack exposes its elite, global security researcher community in 60+ countries to the benefits of CREST. CREST offers a structured entry point for penetration testers globally and could serve as a significant stepping stone to members of the Synack’s Red Team. Synack looks forward to working closely with members of its global community seeking CREST qualifications.
This accreditation is another pillar showing that Synack takes trust seriously. Companies gain intelligence and efficiency by utilizing Synack to address vulnerabilities in a more efficient and effective way while maintaining a strong security posture. Those that work with Synack and use Crowdsourced Penetration Testing for 2+ years are up to 200% more secure than those that do not or have less than a year of usage.
Today, Synack secures >$1 trillion in Fortune 500 revenue, 75% of the top credit card companies, Top 10 consulting firms and security companies, and over 50% of federal cabinet-level agencies. Synack has received awards including 2019 Cyber Defender by CB Insights, CIO Review’s 20 Most Promising Enterprise Security Solution Providers, The Software Report’s Top 25 CyberSecurity Companies, and Wealthfront’s 2019 Career-Launching Companies.
About Synack
Synack, the most trusted crowdsourced security company, delivers comprehensive and continuous penetration testing with actionable results. The company combines the world's most skilled and trusted ethical hackers with AI-enabled technology to create a scalable, effective security solution. Headquartered in Silicon Valley with regional offices around the world, Synack protects leading global banks, federal agencies, DoD classified assets, and close to $1 trillion in Fortune 500 revenue. Synack was founded in 2013 by former US Department of Defense hackers Jay Kaplan, CEO, and Dr. Mark Kuhr, CTO. For more information, please visit www.synack.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190527005215/en/
Contact:
Ellie McCardwell, Synack Communications Email: press@synack.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 10:27:00 CEST | Press release
OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,
The Jury Has Been Announced for the Third Edition of the Reply AI Film Festival, Dedicated to the Best Short Films Generated With Artificial Intelligence29.4.2026 10:00:00 CEST | Press release
Gabriele Salvatores, together with Rob Minkoff, Catherine Hardwicke, Jed Weintrob, Christina Lee Storm, Nils Hartmann, Guillem Martinez Roura, Filippo Rizzante, Giacomo Mineo, Brian Welk and Denise Negri, will judge the short films in competition based on creativity, production quality and the use of Artificial Intelligence. Reply [EXM, STAR: REY], an international group specialized in creating new business models enabled by AI and long committed to guiding younger generations in exploring emerging technologies, presents the jury of the third edition of the Reply AI Film Festival, the international competition aimed at creatives, directors, and filmmakers who want to challenge themselves in producing short films created using Artificial Intelligence tools. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429288361/en/ “Imaginatio Nova” is the theme of the 2026 edition, an invitation to explore a new phase of imagination, wh
Bregal Milestone Announces Majority Growth Investment in CoreGo, a Leading European Open-Loop Payment and Event Technology Company29.4.2026 10:00:00 CEST | Press release
Investment follows over 98% annual growth and supports CoreGo’s continued market expansion Bregal Milestone, a leading European software growth private equity firm, today announced a majority strategic growth investment in CoreGo Oy ("CoreGo" or the "Company"), a leading provider of open-loop payments and integrated technology solutions for festivals, sports events, and venues across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427991105/en/ Founded in Helsinki in 2015 by Hannu Elomaa and CTO Nikoteemu Väänänen, CoreGo has built one of Europe's most differentiated open-loop payment infrastructure and event technology businesses. Serving approximately 250 customers across the Nordics and DACH region, the Company delivers an integrated showtime-critical suite of solutions through CoreGo Cloud, unifying payments, access, networks, and data into a single real-time operating system. CoreGo’s in-house private network
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
